- Latest available (Revised)
- Point in Time (31/03/2014)
- Original (As made)
Version Superseded: 14/08/2012
Point in time view as at 31/03/2014.
The Human Medicines Regulations 2012, SCHEDULE 27 is up to date with all changes known to be in force on or before 19 August 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.
Regulation 260
1. The name of the medicinal product.U.K.
2. The strength and pharmaceutical form of the product.U.K.
3. Where appropriate, whether the product is intended for babies, children or adults.U.K.
4. Where the product contains up to three active substances, the common name of each active substance.U.K.
5. The pharmaco-therapeutic group, or type of activity, of the product, in terms easily comprehensible for the patient.U.K.
6. The product's therapeutic indications.U.K.
7. A list of—U.K.
(a)contra-indications;
(b)appropriate precautions for use;
(c)interactions with other medicinal products which may affect the action of the product;
(d)interactions with other substances, including alcohol, tobacco and foodstuffs, which may affect the action of the product; and
(e)special warnings, if any, relating to the product.
8. The list mentioned in paragraph 7 must—U.K.
(a)take into account the special requirements of particular categories of users (including, in particular, children, pregnant or breastfeeding women, the elderly and persons with specific pathological conditions);
(b)mention, if appropriate, possible effects on the ability to drive vehicles or to operate machinery; and
(c)list any excipients—
(i)if knowledge of the excipients is important for the safe and effective use of the product, and
(ii)the excipients are included in the guidance published pursuant to Article 65 of the 2001 Directive.
9. Instructions for proper use of the product including in particular—U.K.
(a)the dosage;
(b)the method and, if necessary, route of administration;
(c)the frequency of administration (including, if necessary, specifying times at which the product may or must be administered);
(d)the duration of treatment if this is to be limited;
(e)symptoms of an overdose and the action, if any, to be taken in case of an overdose;
(f)what to do if one or more doses have not been taken;
(g)an indication, if necessary, of the risk of withdrawal effects; and
(h)a specific recommendation to consult a doctor or pharmacist, as appropriate, for further explanation of the use of the product.
10. A description of the adverse reactions which may occur in normal use of the medicinal product and, if necessary, the action to be taken in such a case.U.K.
11. A reference to the expiry date printed on the packaging of the product with—U.K.
(a)a warning against using the product after that date;
(b)if appropriate, details of special storage precautions to be taken;
(c)if necessary, a warning concerning visible signs of deterioration;
(d)the full qualitative composition (in active substances and excipients), and the quantitative composition in active substances, using common names, of each presentation of the medicinal product;
(e)for each presentation of the product, the pharmaceutical form and content in weight, volume or units of dosage;
(f)the name and address of the holder of the marketing authorisation, Article 126a authorisation or traditional herbal registration relating to the product and, if applicable, the name of the holder's appointed representative; and
(g)the name and address of the manufacturer of the product.
12. Where the product is authorised under different names in different member States in accordance with Articles 28 to 39 of the 2001 Directive, a list of the names authorised in each member State.U.K.
13. For medicinal products included in the list referred to in Article 23 of Regulation (EC) No 726/2004, the statement: “This medicinal product is subject to additional safety monitoring”.U.K.
14. The statement: “Also you can help to make sure that medicines remain as safe as possible by reporting any unwanted side effects via the internet at www.mhra.gov.uk/yellowcard. Alternatively you can call Freephone 0808 100 3352 (available from 10 a.m. to 2 p.m. Mondays to Fridays) or fill in a paper form available from your local pharmacy.”.U.K.
15. The date on which the package leaflet was last revised.U.K.
16. If a medicinal product contains paracetamol, unless the product is wholly or mainly intended for children twelve years old or younger, the words “Talk to a doctor at once if you take too much of this medicine even if you feel well. This is because too much paracetamol can cause delayed, serious liver damage”.U.K.
17. If a medicinal product contains paracetamol and is wholly or mainly intended for children twelve years old or younger, the words “Talk to a doctor at once if your child takes too much of this medicine even if they seem well. This is because too much paracetamol can cause delayed, serious liver damage”.U.K.
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: